Thomas Starzl, the ‘father of transplantation,’ dies at age 90

Cara Livernois | March 06, 2017 | Health Exec | Precision Medicine

Thomas E. Starzl, MD, PhD, widely known as the “father of transplantation," has died at the age of 90 in his Pittsburg home. Starzl is credited with advancing transplantations from risky ventures to more feasible surgeries for many at-need patients.

Starzls performed the world’s first successful liver transplant in 1967. Starzl helped develop azathioprine and corticosteroid immunosuppression in 1980, helping to make the transplantation process a safer procedure. This advancement lead directly to transplants on patients with end-stage liver, kidney and heart disease.

Over the course of his career, Starzl received more than 200 award and honors including the Lasker-DeBakey Clinical Medical Research Award from the Albert and Mary Lasker Foundation in 2012; the 2004 Presidential National Medal of Science, the nation’s highest scientific honor; the David M. Hume Memorial Award from the National Kidney Foundation; and the Brookdale Award in Medicine presented by the American Medical Association Board of Trustees and the Brookdale Foundation.

Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular Business

Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.

Cardiovascular Business

Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business

FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.

Thomas Starzl, the ‘father of transplantation,’ dies at age 90

Related Content

Around the web